伊立替康每周方案联合沙利度胺治疗晚期原发性肝癌的疗效观察
|
摘要
目的探讨伊立替康每周方案联合沙利度胺治疗晚期原发性肝癌的治疗效果。方法将60例晚期原发性肝癌患者随机分为观察组和对照组,各30例。2组均采用常规肝癌治疗手段,观察组在此基础之上辅以伊立替康每周方案联合沙利度胺联合治疗。治疗3个月后,对比分析2组患者的近期缓解率、治疗前后AFP的水平以及化疗后毒副作用的发生率。结果 2组近期疗效相比,差异具有统计学意义(χ~2=5. 455,P=0. 023)。AFP检测结果显示,2组治疗前后AFP滴度差异均具有统计学意义(t=10. 98,P=0. 00),且治疗后观察组AFP水平明显低于对照组(P <0. 05)。2组患者消化道反应和腹泻的发生率存在统计学差异(χ~2=4. 320,5. 963; P=0. 038,0. 015)。结论伊立替康每周方案联合沙利度胺对晚期原发性肝癌具有更好的疗效,化疗后毒副作用相对轻微,有望给临床晚期原发性肝癌的治疗带来新的方向。
Objective To explore the therapeutic effect of irinotecan weekly regimen combined with thalidomide in the treatment of advanced primary liver cancer. Methods 60 patients with advanced primary liver cancer were randomly divided into the observation group and the control group,30 cases of each. The 2 groups were treated with conventional liver cancer treatment.The observation group was supplemented with irinotecan weekly regimen combined with thalidomide. After 3 months of treatment,the short-term remission rate,the level of AFP before and after treatment,and the incidence of side effects after chemotherapy were compared and analyzed. Results The difference between the 2 groups was statistically significant( χ~2= 5. 455,P = 0. 023). The results of AFP test showed that the difference of AFP titers before and after treatment was significant( t = 10. 98,P = 0. 00),and the level of AFP in the observation group was significantly lower than that of the control group( P < 0. 05). There was a significant difference in the incidence of digestive tract reaction and diarrhea between the 2 groups( χ~2= 4. 320,5. 963; P = 0. 038,0. 015).Conclusion The irinotecan weekly regimen combined with thalidomide has a better effect on advanced primary liver cancer,and the toxic side effects after chemotherapy are relatively mild,which is expected to bring new directions for the treatment of advanced primary liver cancer.
Objective To explore the therapeutic effect of irinotecan weekly regimen combined with thalidomide in the treatment of advanced primary liver cancer. Methods 60 patients with advanced primary liver cancer were randomly divided into the observation group and the control group,30 cases of each. The 2 groups were treated with conventional liver cancer treatment.The observation group was supplemented with irinotecan weekly regimen combined with thalidomide. After 3 months of treatment,the short-term remission rate,the level of AFP before and after treatment,and the incidence of side effects after chemotherapy were compared and analyzed. Results The difference between the 2 groups was statistically significant( χ~2= 5. 455,P = 0. 023). The results of AFP test showed that the difference of AFP titers before and after treatment was significant( t = 10. 98,P = 0. 00),and the level of AFP in the observation group was significantly lower than that of the control group( P < 0. 05). There was a significant difference in the incidence of digestive tract reaction and diarrhea between the 2 groups( χ~2= 4. 320,5. 963; P = 0. 038,0. 015).Conclusion The irinotecan weekly regimen combined with thalidomide has a better effect on advanced primary liver cancer,and the toxic side effects after chemotherapy are relatively mild,which is expected to bring new directions for the treatment of advanced primary liver cancer.
引文
[1]Ghevariya V,Sandar N,Patel K,et al.Knowing What's Out There:Awareness of non-alcoholic fatty liver disease[J].Front Med,2014,1:4.
[2]Kaewpitoon SJ,Rujirakul R,Wakkuwattapong P,et al.Development of a health education modification program regarding liver flukes and cholangiocarcinoma in high risk areas of nakhon ratchasima province using self-efficacy and motivation theory[J].Asian Pac J Cancer Prev,2016,17(6):2947-2951.
[3]Xu C,Zhang Y,Peng L,et al.Optimal modality for detecting distant metastasis in primary nasopharyngeal carcinoma during initial staging:A systemic review and meta-analysis of 1774 patients[J].J Cancer,2017,8(7):1238-1248.
[4]Beal EW,Tumin D,Kabir A,et al.Trends in the mortality of hepatocellular carcinoma in the united states[J].J Gastrointest Surg,2017,21(12):2033-2038.
[5]Jones NL,Chen L,Chatterjee S,et al.National trends in extended procedures for ovarian cancer debulking surgery[J].Int J Gynecol Cancer,2018,28(1):19-25.
[6]Shiraishi K,Kubo Y,Majima Y,et al.Clinical evaluation of1-hexylcarbamoyl-5-fluorouracil(hcfu)in hepatocellular carcinoma[J].Gan to kagaku ryoho Cancer&chemotherapy,1984,11(11):2348-2355.
[7]Lencioni M,Falcone A,Allegrini G,et al.Oral doxifluridine in advanced hepatocellular carcinoma:A phase ii study[J].Oncology,2000,59(3):204-209.
[8]欧阳学农,余宗阳,杜建.卡培他滨联合肝动脉栓塞化疗治疗中晚期肝癌疗效[J].中国肿瘤,2009,18(6):518-520.
[9]Lv P,Luo HS,Zhou XP,et al.Thalidomide prevents rat liver cirrhosis via inhibition of oxidative stress[J].Pathol Res Pract,2006,202(11):777-788.
[10]Han SH,Park SH,Kim JH,et al.Thalidomide for treatingmetastatic hepatocellular carcinoma:A pilot study[J].Korean J Intern Med,2006,21(4):225-229.
[11]Chuah B,Lim R,Boyer M,et al.Multi-centre phase ii trial of thalidomide in the treatment of unresectable hepatocellular carcinoma[J].Acta oncologica(Stockholm,Sweden),2007,46(2):234-238.
[12]Chiou HE,Wang TE,Wang YY,et al.Efficacy and safety of thalidomide in patients with hepatocellular carcinoma[J].World J Gastroenterol,2006,12(43):6955-6960.
[13]马旭辉,苗振静,李霞,等.沙利度胺联合GEMOX方案治疗中晚期肝癌的临床观察[J].实用癌症杂志,2011,26(5):498-499.
[2]Kaewpitoon SJ,Rujirakul R,Wakkuwattapong P,et al.Development of a health education modification program regarding liver flukes and cholangiocarcinoma in high risk areas of nakhon ratchasima province using self-efficacy and motivation theory[J].Asian Pac J Cancer Prev,2016,17(6):2947-2951.
[3]Xu C,Zhang Y,Peng L,et al.Optimal modality for detecting distant metastasis in primary nasopharyngeal carcinoma during initial staging:A systemic review and meta-analysis of 1774 patients[J].J Cancer,2017,8(7):1238-1248.
[4]Beal EW,Tumin D,Kabir A,et al.Trends in the mortality of hepatocellular carcinoma in the united states[J].J Gastrointest Surg,2017,21(12):2033-2038.
[5]Jones NL,Chen L,Chatterjee S,et al.National trends in extended procedures for ovarian cancer debulking surgery[J].Int J Gynecol Cancer,2018,28(1):19-25.
[6]Shiraishi K,Kubo Y,Majima Y,et al.Clinical evaluation of1-hexylcarbamoyl-5-fluorouracil(hcfu)in hepatocellular carcinoma[J].Gan to kagaku ryoho Cancer&chemotherapy,1984,11(11):2348-2355.
[7]Lencioni M,Falcone A,Allegrini G,et al.Oral doxifluridine in advanced hepatocellular carcinoma:A phase ii study[J].Oncology,2000,59(3):204-209.
[8]欧阳学农,余宗阳,杜建.卡培他滨联合肝动脉栓塞化疗治疗中晚期肝癌疗效[J].中国肿瘤,2009,18(6):518-520.
[9]Lv P,Luo HS,Zhou XP,et al.Thalidomide prevents rat liver cirrhosis via inhibition of oxidative stress[J].Pathol Res Pract,2006,202(11):777-788.
[10]Han SH,Park SH,Kim JH,et al.Thalidomide for treatingmetastatic hepatocellular carcinoma:A pilot study[J].Korean J Intern Med,2006,21(4):225-229.
[11]Chuah B,Lim R,Boyer M,et al.Multi-centre phase ii trial of thalidomide in the treatment of unresectable hepatocellular carcinoma[J].Acta oncologica(Stockholm,Sweden),2007,46(2):234-238.
[12]Chiou HE,Wang TE,Wang YY,et al.Efficacy and safety of thalidomide in patients with hepatocellular carcinoma[J].World J Gastroenterol,2006,12(43):6955-6960.
[13]马旭辉,苗振静,李霞,等.沙利度胺联合GEMOX方案治疗中晚期肝癌的临床观察[J].实用癌症杂志,2011,26(5):498-499.